Frontlight ResearchEarly access
Active, not recruitingPhase 1/2
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
Key facts
- Who runs it
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Where
- Torrance, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1/2
- People taking part
- 14 people, planned
- Started
- 5 Jun 2017
- Expected to end
- Feb 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Adalimumab Injection [Humira]
- Saline Solution for Injection
- Record updated
- 2 February 2026
Who can take part
- Age
- 5 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (23)Hide the full registry criteria
Who can take part
- Male or female ≥5 years of age
- Diagnosis of MPS I, II or VI
- Treatment with ERT for ≥1 year or no treatment with ERT for ≥1 year
- Weight ≥15 kg
- Significant bodily pain reported by the CHQ-PF50 or SF-36 (> 1 SD more severe [below] than the general population mean)
- ≥ 3 joints with limitations in motion; and Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 17 years of age, assent must also be provided
Who cannot take part
- History of HCT less than 2 years prior to enrollment
- Immune suppression therapy less than 1 year prior to enrollment
- Participation in simultaneous therapeutic study that involves an investigational study drug or agent within 4 weeks of study enrollment
- Requirement for live vaccine exposure that would be expected to occur during the time frame of the study; or
- Any other social or medical condition that the Investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study
- Active graft versus host disease
- Current diagnosis or history of lymphoma or other malignancy
- Current active infection
- History of serious opportunistic infection (e.g., bacterial [Legionella and Listeria]; tuberculosis [TB]; invasive fungal infections; or viral, parasitic, and other opportunistic infections)
- Congestive heart failure defined by an ejection fracture <50% measured by ECHO
- Demyelinating disorders (e.g., central nervous system [CNS] disorders including multiple sclerosis and optic neuritis and peripheral nervous system disorders including Guillain-Barre syndrome)
- Hepatitis B infection (active or chronic carrier)
- Known or suspected allergy to adalimumab or related products
- Positive TB skin test, positive Quantiferon-TB Gold TB test, positive chest X-ray, or a recent exposure to TB
- Hematologic abnormalities (e.g., pancytopenia, aplastic anemia)
- Latex sensitivity
- Pregnancy or breastfeeding
Where in United States
- The Lundquist Institute at Harbor UCLA Medical CenterTorrance, United States
About the trial
What the trial wants to find out
Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.
The 3 groups in the trial
- AdalimumabTreatment being tested
20 mg subQ every other week (weight 15to \<30 kg) 40 mg subQ every other week (weight ≥30 kg). Non-responders will be escalated to weekly dosing.
Treatment: Adalimumab Injection [Humira]
- PlaceboPlacebo, for comparison
Saline placebo comparator
Treatment: Saline Solution for Injection
- Open-label adalimumabTreatment being tested
Open-label extension of adalimumab dose
Treatment: Adalimumab Injection [Humira]
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1/2 Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II, and VI
- Record updated
- 2 February 2026